UVA1 phototherapy is effective in darker skin: A review of 101 patients of Fitzpatrick skin types I-V

H. T. Jacobe, R. Cayce, J. Nguyen

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Studies suggest ultraviolet (UV) A1 phototherapy is efficacious and safe in treating a variety of skin disorders. However, most reports evaluating the benefits of UVA1 phototherapy have been from Europe, focusing on a predominantly Caucasian population. Darker skin types have been evaluated only sparingly; none the less, it is widely held that these patients respond poorly to UVA1 phototherapy due to increased pigmentation. Objectives: We aim to compare efficacy (clinical improvement scores) of UVA1 phototherapy among Fitzpatrick skin types. Methods: A retrospective analysis of 101 patients receiving UVA1 treatment at the University of Texas Southwestern Medical Center in Dallas, TX was performed. Data on Fitzpatrick skin type and cumulative UVA1 doses were collected. Clinical improvement scores based on body surface area, erythema, induration, sclerosis, pigmentation, and symptoms of pain or pruritus were obtained. Results: In the population studied, with morphoea and scleroderma being the most frequent diagnoses, improvement scores from UVA1 phototherapy and mean cumulative UVA1 doses were not significantly different among the Fitzpatrick skin types evaluated. Furthermore, little or no correlation was found between improvement score and skin type. Conclusions: Data indicate skin pigmentation as graded by Fitzpatrick skin type does not significantly influence the efficacy of UVA1 phototherapy. Thus, UVA1 should be considered as a therapeutic option in more darkly pigmented patients.

Original languageEnglish (US)
Pages (from-to)691-696
Number of pages6
JournalBritish Journal of Dermatology
Volume159
Issue number3
DOIs
StatePublished - Sep 2008

Fingerprint

Phototherapy
Skin
Pigmentation
Localized Scleroderma
Skin Pigmentation
Body Surface Area
Sclerosis
Erythema
Pruritus
Population
Pain
Therapeutics

Keywords

  • Fitzpatrick skin type
  • Morphoea
  • Phototherapy
  • Scleroderma
  • UVA1

ASJC Scopus subject areas

  • Dermatology

Cite this

UVA1 phototherapy is effective in darker skin : A review of 101 patients of Fitzpatrick skin types I-V. / Jacobe, H. T.; Cayce, R.; Nguyen, J.

In: British Journal of Dermatology, Vol. 159, No. 3, 09.2008, p. 691-696.

Research output: Contribution to journalArticle

@article{ae4a39885543487196744ac85fdf9698,
title = "UVA1 phototherapy is effective in darker skin: A review of 101 patients of Fitzpatrick skin types I-V",
abstract = "Background: Studies suggest ultraviolet (UV) A1 phototherapy is efficacious and safe in treating a variety of skin disorders. However, most reports evaluating the benefits of UVA1 phototherapy have been from Europe, focusing on a predominantly Caucasian population. Darker skin types have been evaluated only sparingly; none the less, it is widely held that these patients respond poorly to UVA1 phototherapy due to increased pigmentation. Objectives: We aim to compare efficacy (clinical improvement scores) of UVA1 phototherapy among Fitzpatrick skin types. Methods: A retrospective analysis of 101 patients receiving UVA1 treatment at the University of Texas Southwestern Medical Center in Dallas, TX was performed. Data on Fitzpatrick skin type and cumulative UVA1 doses were collected. Clinical improvement scores based on body surface area, erythema, induration, sclerosis, pigmentation, and symptoms of pain or pruritus were obtained. Results: In the population studied, with morphoea and scleroderma being the most frequent diagnoses, improvement scores from UVA1 phototherapy and mean cumulative UVA1 doses were not significantly different among the Fitzpatrick skin types evaluated. Furthermore, little or no correlation was found between improvement score and skin type. Conclusions: Data indicate skin pigmentation as graded by Fitzpatrick skin type does not significantly influence the efficacy of UVA1 phototherapy. Thus, UVA1 should be considered as a therapeutic option in more darkly pigmented patients.",
keywords = "Fitzpatrick skin type, Morphoea, Phototherapy, Scleroderma, UVA1",
author = "Jacobe, {H. T.} and R. Cayce and J. Nguyen",
year = "2008",
month = "9",
doi = "10.1111/j.1365-2133.2008.08672.x",
language = "English (US)",
volume = "159",
pages = "691--696",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - UVA1 phototherapy is effective in darker skin

T2 - A review of 101 patients of Fitzpatrick skin types I-V

AU - Jacobe, H. T.

AU - Cayce, R.

AU - Nguyen, J.

PY - 2008/9

Y1 - 2008/9

N2 - Background: Studies suggest ultraviolet (UV) A1 phototherapy is efficacious and safe in treating a variety of skin disorders. However, most reports evaluating the benefits of UVA1 phototherapy have been from Europe, focusing on a predominantly Caucasian population. Darker skin types have been evaluated only sparingly; none the less, it is widely held that these patients respond poorly to UVA1 phototherapy due to increased pigmentation. Objectives: We aim to compare efficacy (clinical improvement scores) of UVA1 phototherapy among Fitzpatrick skin types. Methods: A retrospective analysis of 101 patients receiving UVA1 treatment at the University of Texas Southwestern Medical Center in Dallas, TX was performed. Data on Fitzpatrick skin type and cumulative UVA1 doses were collected. Clinical improvement scores based on body surface area, erythema, induration, sclerosis, pigmentation, and symptoms of pain or pruritus were obtained. Results: In the population studied, with morphoea and scleroderma being the most frequent diagnoses, improvement scores from UVA1 phototherapy and mean cumulative UVA1 doses were not significantly different among the Fitzpatrick skin types evaluated. Furthermore, little or no correlation was found between improvement score and skin type. Conclusions: Data indicate skin pigmentation as graded by Fitzpatrick skin type does not significantly influence the efficacy of UVA1 phototherapy. Thus, UVA1 should be considered as a therapeutic option in more darkly pigmented patients.

AB - Background: Studies suggest ultraviolet (UV) A1 phototherapy is efficacious and safe in treating a variety of skin disorders. However, most reports evaluating the benefits of UVA1 phototherapy have been from Europe, focusing on a predominantly Caucasian population. Darker skin types have been evaluated only sparingly; none the less, it is widely held that these patients respond poorly to UVA1 phototherapy due to increased pigmentation. Objectives: We aim to compare efficacy (clinical improvement scores) of UVA1 phototherapy among Fitzpatrick skin types. Methods: A retrospective analysis of 101 patients receiving UVA1 treatment at the University of Texas Southwestern Medical Center in Dallas, TX was performed. Data on Fitzpatrick skin type and cumulative UVA1 doses were collected. Clinical improvement scores based on body surface area, erythema, induration, sclerosis, pigmentation, and symptoms of pain or pruritus were obtained. Results: In the population studied, with morphoea and scleroderma being the most frequent diagnoses, improvement scores from UVA1 phototherapy and mean cumulative UVA1 doses were not significantly different among the Fitzpatrick skin types evaluated. Furthermore, little or no correlation was found between improvement score and skin type. Conclusions: Data indicate skin pigmentation as graded by Fitzpatrick skin type does not significantly influence the efficacy of UVA1 phototherapy. Thus, UVA1 should be considered as a therapeutic option in more darkly pigmented patients.

KW - Fitzpatrick skin type

KW - Morphoea

KW - Phototherapy

KW - Scleroderma

KW - UVA1

UR - http://www.scopus.com/inward/record.url?scp=49749134768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49749134768&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2133.2008.08672.x

DO - 10.1111/j.1365-2133.2008.08672.x

M3 - Article

C2 - 18544076

AN - SCOPUS:49749134768

VL - 159

SP - 691

EP - 696

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 3

ER -